Nanomedicine Market Size Expected to Reach USD 562.93 Bn by 2032 [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
Ottawa, April 03, 2024 (GLOBE NEWSWIRE) -- The global nanomedicine market size was valued at USD 219.34 billion in 2023 and is predicted to hit around USD 494.62 billion by 2031, a study published by Towards Healthcare a sister firm of Precedence Research. Report Highlights: Clinical oncology indication leads the pack, dominating the market with a commanding 45% market share in 2023. Drug delivery application represents the biggest chunk, with a 36% market share in 2023. North America leads the charge, holding 38% market share in 2023. According to recent data, around 100+ nanomedicines have been commercially marketed, with almost 550+ nanomedicines under clinical trials. Nanomedicine involves creating and utilizing tiny structures or devices, typically between 1 and 100 nanometers in size, for medical purposes such as diagnosis and treatment. These nanoscale objects or tools, including nano-robots, skin patches, or other nanostructured materials, leverage their unique pr
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets [Yahoo! Finance]Yahoo! Finance
- Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsBusiness Wire
- Neurocrine Biosciences' Huntington's disease drug gets FDA approval [Reuters]Reuters
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)Business Wire
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)Business Wire
TEVA
Earnings
- 1/31/24 - Beat
TEVA
Sec Filings
- 4/18/24 - Form 8-K
- 4/16/24 - Form DEFA14A
- 4/16/24 - Form ARS
- TEVA's page on the SEC website